The month ahead: May’s upcoming events
ASCO looms, while FDA decisions are due on Enhertu and Inqovi.
Roche sounds another warning over co-stimulation
The company drops the anti-CD19 x 4-1BB project englumafusp alfa.
Licensing analysis: Chinese deals abound
AbbVie’s PD-1 x VEGF agreement with RemeGen was the first-quarter’s biggest.
Roche flunks its first-line degrader test
Persevera is a bust, but Roche hasn’t given up on the front line.
The month ahead: March’s upcoming events
Decisions and readouts loom for the SERDs Astra’s camizestrant and Roche’s giredestrant.
No differentiation for Roche's degrader
Just like other oral SERDs, filing is restricted to the ESR1-mutant population.
Roche follows Pfizer out of LTβR
The group also discontinues a mystery asset, and a Tecentriq trial in periadjuvant lung cancer.
Licensing analysis: Takeda saves the day
The Japanese group’s $1.2bn deal with Innovent is by far the biggest of the fourth quarter.
The month ahead: January’s remaining events
JP Morgan approaches.
